EquitySector - HealthcareVery High Risk
Direct
NAV (11-Jul-25)
Returns (Since Inception)
Fund Size
₹3,849 Cr
Expense Ratio
0.90%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+18.94%
+13.44% (Cat Avg.)
3 Years
+29.51%
+24.01% (Cat Avg.)
5 Years
+25.33%
+21.85% (Cat Avg.)
10 Years
+12.86%
+13.66% (Cat Avg.)
Since Inception
+18.33%
— (Cat Avg.)
Equity | ₹3,732.99 Cr | 96.98% |
Debt | ₹2.94 Cr | 0.08% |
Others | ₹113.32 Cr | 2.94% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹469.2 Cr | 12.19% |
Divi's Laboratories Ltd | Equity | ₹299.62 Cr | 7.78% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹267.96 Cr | 6.96% |
Lonza Group Ltd ADR | Equity | ₹183.13 Cr | 4.76% |
Cipla Ltd | Equity | ₹180.71 Cr | 4.69% |
Lupin Ltd | Equity | ₹162.79 Cr | 4.23% |
Mankind Pharma Ltd | Equity | ₹129.91 Cr | 3.37% |
Abbott India Ltd | Equity | ₹128.41 Cr | 3.34% |
Fortis Healthcare Ltd | Equity | ₹127.12 Cr | 3.30% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹125.17 Cr | 3.25% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹121.25 Cr | 3.15% |
Jupiter Life Line Hospitals Ltd | Equity | ₹119.78 Cr | 3.11% |
Treps | Cash - Repurchase Agreement | ₹119.43 Cr | 3.10% |
Acutaas Chemicals Ltd | Equity | ₹114.44 Cr | 2.97% |
Poly Medicure Ltd | Equity | ₹112.64 Cr | 2.93% |
Laurus Labs Ltd | Equity | ₹108.73 Cr | 2.82% |
Aether Industries Ltd | Equity | ₹106.65 Cr | 2.77% |
Torrent Pharmaceuticals Ltd | Equity | ₹102.25 Cr | 2.66% |
Rainbow Childrens Medicare Ltd | Equity | ₹99.97 Cr | 2.60% |
Gland Pharma Ltd | Equity | ₹99.01 Cr | 2.57% |
Alkem Laboratories Ltd | Equity | ₹98.78 Cr | 2.57% |
Concord Biotech Ltd | Equity | ₹91.98 Cr | 2.39% |
Aurobindo Pharma Ltd | Equity | ₹90.78 Cr | 2.36% |
Biocon Ltd | Equity | ₹88.93 Cr | 2.31% |
Cohance Lifesciences Ltd | Equity | ₹61.95 Cr | 1.61% |
Vijaya Diagnostic Centre Ltd | Equity | ₹59.12 Cr | 1.54% |
Pfizer Ltd | Equity | ₹56.78 Cr | 1.47% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹46.83 Cr | 1.22% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹42.72 Cr | 1.11% |
Gufic Biosciences Ltd | Equity | ₹36.41 Cr | 0.95% |
Net Receivable / Payable | Cash - Collateral | ₹-6.11 Cr | 0.16% |
India (Republic of) | Bond - Short-term Government Bills | ₹2.94 Cr | 0.08% |
Large Cap Stocks
27.32%
Mid Cap Stocks
28.44%
Small Cap Stocks
36.46%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,511.91 Cr | 91.24% |
Basic Materials | ₹221.09 Cr | 5.74% |
Standard Deviation
This fund
13.71%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
1.57
Cat. avg.
1.14
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.10
Higher the better
Since June 2011
ISIN INF200K01UP2 | Expense Ratio 0.90% | Exit Load No Charges | Fund Size ₹3,849 Cr | Age 12 years 6 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹11,22,108 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Your principal amount will be at Very High Risk
EquitySector - HealthcareVery High Risk
Direct
NAV (11-Jul-25)
Returns (Since Inception)
Fund Size
₹3,849 Cr
Expense Ratio
0.90%
ISIN
INF200K01UP2
Minimum SIP
₹1,000
Exit Load
No Charges
Inception Date
01 Jan 2013
Your principal amount will be at Very High Risk
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+18.94%
+13.44% (Cat Avg.)
3 Years
+29.51%
+24.01% (Cat Avg.)
5 Years
+25.33%
+21.85% (Cat Avg.)
10 Years
+12.86%
+13.66% (Cat Avg.)
Since Inception
+18.33%
— (Cat Avg.)
Equity | ₹3,732.99 Cr | 96.98% |
Debt | ₹2.94 Cr | 0.08% |
Others | ₹113.32 Cr | 2.94% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹469.2 Cr | 12.19% |
Divi's Laboratories Ltd | Equity | ₹299.62 Cr | 7.78% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹267.96 Cr | 6.96% |
Lonza Group Ltd ADR | Equity | ₹183.13 Cr | 4.76% |
Cipla Ltd | Equity | ₹180.71 Cr | 4.69% |
Lupin Ltd | Equity | ₹162.79 Cr | 4.23% |
Mankind Pharma Ltd | Equity | ₹129.91 Cr | 3.37% |
Abbott India Ltd | Equity | ₹128.41 Cr | 3.34% |
Fortis Healthcare Ltd | Equity | ₹127.12 Cr | 3.30% |
Aster DM Healthcare Ltd Ordinary Shares | Equity | ₹125.17 Cr | 3.25% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹121.25 Cr | 3.15% |
Jupiter Life Line Hospitals Ltd | Equity | ₹119.78 Cr | 3.11% |
Treps | Cash - Repurchase Agreement | ₹119.43 Cr | 3.10% |
Acutaas Chemicals Ltd | Equity | ₹114.44 Cr | 2.97% |
Poly Medicure Ltd | Equity | ₹112.64 Cr | 2.93% |
Laurus Labs Ltd | Equity | ₹108.73 Cr | 2.82% |
Aether Industries Ltd | Equity | ₹106.65 Cr | 2.77% |
Torrent Pharmaceuticals Ltd | Equity | ₹102.25 Cr | 2.66% |
Rainbow Childrens Medicare Ltd | Equity | ₹99.97 Cr | 2.60% |
Gland Pharma Ltd | Equity | ₹99.01 Cr | 2.57% |
Alkem Laboratories Ltd | Equity | ₹98.78 Cr | 2.57% |
Concord Biotech Ltd | Equity | ₹91.98 Cr | 2.39% |
Aurobindo Pharma Ltd | Equity | ₹90.78 Cr | 2.36% |
Biocon Ltd | Equity | ₹88.93 Cr | 2.31% |
Cohance Lifesciences Ltd | Equity | ₹61.95 Cr | 1.61% |
Vijaya Diagnostic Centre Ltd | Equity | ₹59.12 Cr | 1.54% |
Pfizer Ltd | Equity | ₹56.78 Cr | 1.47% |
Akums Drugs and Pharmaceuticals Ltd | Equity | ₹46.83 Cr | 1.22% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹42.72 Cr | 1.11% |
Gufic Biosciences Ltd | Equity | ₹36.41 Cr | 0.95% |
Net Receivable / Payable | Cash - Collateral | ₹-6.11 Cr | 0.16% |
India (Republic of) | Bond - Short-term Government Bills | ₹2.94 Cr | 0.08% |
Large Cap Stocks
27.32%
Mid Cap Stocks
28.44%
Small Cap Stocks
36.46%
AAA
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹3,511.91 Cr | 91.24% |
Basic Materials | ₹221.09 Cr | 5.74% |
Standard Deviation
This fund
13.71%
Cat. avg.
15.76%
Lower the better
Sharpe Ratio
This fund
1.57
Cat. avg.
1.14
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
2.10
Higher the better
Since June 2011
ISIN INF200K01UP2 | Expense Ratio 0.90% | Exit Load No Charges | Fund Size ₹3,849 Cr | Age 12 years 6 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Total AUM
₹11,22,108 Cr
Address
C-38 & 39, G Block, Bandra Kurla Complex, Mumbai, 400 051
Get your portfolio reviewed by experts
Download Wealth Monitor App
Track and monitor all
your investments